R 715 TFA

• Bioactivity:

  R 715, a bradykinin B1 receptor antagonist, inhibits contractions in isolated human umbilical cords that express bradykinin B1 receptors (pA2 = 8.49) . When administered at doses of 200, 400, and 600 µg/kg, R 715 enhances latency to tail withdrawal in the tail-flick test for diabetic neuropathy mouse models induced by streptozotocin (STZ), signaling potential analgesic properties. Furthermore, at a 1 mg/kg per day dosage, it mitigates symptoms in a mouse model of experimental autoimmune encephalomyelitis (EAE) induced by MOG35-55 antigen peptide, such as reducing hind limb weakness and paralysis, improving gait symmetry, and decreasing spinal inflammation, neuron demyelination, and lesion monocyte invasion. Additionally, R 715 at 0.01 nmol/animal, administered intracerebroventricularly (i.c.v.), lowers mean arterial blood pressure and increases heart rate in spontaneously hypertensive rats, indicating cardiovascular effects.

• Smiles:

  O=C (N1[C@@H] (CCC1) C (NCC (N[C@H] (C (N[C@@H] (CO) C (N[C@@H] (C (N[C@H] (C (O) =O) [C@@H] (C) CC) =O) CC2=CC3=C (C=CC=C3) C=C2) =O) =O) CC4=CC=CC=C4) =O) =O) [C@H]5N (CCC5) C ([C@H] (CCCNC (N) =N) NC ([C@@H] (NC (C) =O) CCCCN) =O) =O.OC (C (F) (F) F) =O

• Molecular Formula:

  C57H81N13O12.XCF3COOH

• Molecular Weight:

  1140.33

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C